urrent guidelines recommend the use of standard lipid measures, including the total to high-density lipoprotein cholesterol ratio, inexpensive and readily available, for routine cardiovascular disease risk assessment. 1 Other studies and consensus panels, however, have suggested that the number of circulating atherogenic particles (and apoB as a surrogate) provide better risk prediction than standard lipid measures. 2 Tests such as the Vertical Auto Profile (Atherotech, Birmingham, AL), which determines the cholesterol content of very low density lipoprotein, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) subclasses, and patterns of LDL size; and nuclear magnetic resonance (NMR) spectroscopy, which determines the sizes and concentrations of lipoprotein particles, have been described as improving the predictive power of lipid measurements. 3,4 At times, there has been intense debate in the literature over the relative merits of these tests versus the standard lipid profile. 5 The clinical popularity of lipid subfractionation and particle number and size measurements varies widely, but it is not uncommon to have patients specifically ask for these tests, and multiple web sites suggest that, if your physician is not knowledgeable about such studies, he or she is simply not to be thought of as keeping up with the times.
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The data, however, do not consistently support the additional value of these studies when added to standard lipid profile measurement. Ingelsson and colleagues 6 used data from the Framingham Heart Study to assess the incremental utility of apolipoproteins over traditional lipids for coronary heart disease prediction. They followed 3322 middle-aged participants (53% women) for a median of 15 years. The primary outcome measure was incidence of first coronary heart disease event, including myocardial infarction, angina pectoris, coronary insufficiency, or coronary heart disease death. In both men and women, models using the apoB:apoA 1 ratio demonstrated performance characteristics comparable to, but not better than that for other lipid ratios. The apoB:apoA 1 ratio did not improve prediction of coronary heart disease risk in a model containing all components of the Framingham risk score, including total cholesterol: HDL cholesterol.
The added value of NMR spectroscopic measurement of lipoprotein particle number and size was studied by Mora and colleagues 7 in 27 673 initially healthy women in the Women's Health Study followed up for incident cardiovascular disease over an 11-year period. Hazard ratios for NMRmeasured lipoprotein particle concentration were comparable but not superior to standard lipids. Essentially no reclassification improvement was found with the addition of LDL particle concentration or apoB100 to a model that already included the total:HDL cholesterol ratio and nonlipid risk factors. Even though LDL NMR particle concentration performed well for cardiovascular disease risk prediction and was similar in risk to apoB100, neither measurement was better than the total:HDL cholesterol ratio that is readily obtained from a standard lipid panel.
The article by Parish and colleagues 8 in this issue of Circulation adds importantly to this debate. In contrast to the observational studies described above, the authors use data from the Medical Research Council/British Heart Foundation Heart Protection Study, a blinded, randomized trial of statin and antioxidant therapy in Ͼ20 000 high-risk men and women with an average 5.3-year follow-up, during which time Ͼ5000 vascular events occurred, permitting separate evaluations of associations of lipoprotein subclasses with coronary and other cardiac events, ischemic strokes, and revascularization procedures. The predictive power of standard cholesterol fractions was compared with measurements of apoB and apoA 1 and lipoprotein particles assessed by NMR, and subclass levels, as well. The various measures were all strongly correlated and had similar predictive value for major vascular events, and LDL subclasses provided little additional information. Likewise, the particle distribution measures did not add predictive value. This was true across varying levels of risk, nor did it differ by sex.
The totality of the evidence from these and other studies does not support measurement of apolipoproteins and particle subclasses as adding meaningfully to our ability to predict risk of atherosclerotic disease. But perhaps more importantly, we need to recognize that our hunt for progressively finer discriminatory tools for risk assessment is a misplaced effort. The underlying assumption is that we have difficulty recognizing who is at risk. This is not the case. We know how to recognize those at risk for atherosclerotic disease. It used to be said that many myocardial infarctions occur in people without abnormalities of traditional risk factors. This is a myth. Pooling data from the Chicago Heart Association Detection Project in Industry, the Framingham Heart Study, and the Multiple Risk Factor Intervention Trial demonstrated that for fatal coronary heart disease (a total of 20 995 deaths), exposure to at least 1 clinically elevated major risk factor ranged from 87% to 100%. 9 Risk factors were here defined as a total cholesterol of at least 240 mg/dL, systolic blood pressure of at least 140 mm Hg, diastolic blood pressure of at least 90 mm Hg, cigarette smoking, and clinical diabetes, an analysis that did not even use LDL, HDL, or total cholesterol:HDL ratio. Our greatest problem is delivering appropriate risk factor modification to those in whom the risk is obvious; it is useful to seek better discrimination of risk in those at the margins, but it is not where our greatest effort should be focused.
In 1965, Fredrickson and Lees 10 described "A System for Phenotyping Hyperlipoproteinemia," in which they replaced ultracentrifugation with the much more accessible electrophoretic analysis, and described a taxonomy for the classification of hyperlipidemia. They noted that each of the described types tended to respond better to specifically targeted therapeutic approaches. Ten years later, however, Fredrickson 11 published another article in this journal now entitled "It's Time to Be Practical." In the intervening decade, Fredrickson noted that a technique that worked well for categorizing familial hyperlipidemias did not separate individuals nearly as well when extended to larger populations containing a high proportion of more moderate abnormalities. Two of his conclusions are as appropriate today as they were 37 years ago:
• "…the majority of patients with hyperlipidemia can be detected, sorted and managed by lipid analyses alone." • "…the conversion of lipid concentrations to patterns of hyperlipoproteinemia offers the clearest view of physiological mechanisms and metabolic derangements alike. Nevertheless, there are practical limits to obtaining this illumination …."
The analysis of lipid subfractions and NMR lipid particle analysis is important in improving our understanding of lipid physiology, but, as was the case with the Fredrickson classification, it is time to be practical. The present study adds to a body of evidence demonstrating that it is not necessary to go beyond standard lipid analyses in defining their contribution to cardiovascular risk. Additional studies add cost and do not add to clinical utility. The "Choosing Wisely" campaign has emphasized the importance of controlling healthcare costs by avoiding additional screening tests that have not been shown to be useful for improving health. 12 As an example, the cost to my institution for a standard 3-component lipid profile with LDL calculation is $5.79. Adding a direct LDL (automatically done when triglycerides are Ͼ350 mg/dL) brings the cost to $7.72. A lipoprotein subfractionation by ultracentrifugation costs $58.38, and NMR particle number and size determination adds an additional $72.96.
A physician can, in quite a short interval of time, easily categorize a patient's risk. That component of risk related to lipids is also easily assessed with inexpensive and wellstandardized measurements. Our greatest effort must be directed toward the overall reduction of cardiovascular risk: behavior change with regard to smoking, obesity, unhealthy diet, inadequate physical activity, and psychosocial factors such as stress and depression; greater attention to the health of our children and the facilitation of healthy behavior throughout the life course 13 ; prescription of appropriate medication for hyperlipidemia and hypertension with attendant emphasis on medication adherence; and systematic public health and societal strategies that support beneficial change. The tools we have available to define cardiovascular risk are quite adequate to the task; we now need to improve their utilization so as to further reduce the population burden of cardiovascular disease.
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